11 Evidence-Based Treatments for Low Libido in Menopause Beyond Telling Women to 'Relax'
The thing that frustrated me most wasn't the symptom itself — it was being handed a pamphlet about 'relationship stress' when what I actually needed was someone to explain what oestrogen withdrawal does to genital tissue and brain chemistry. Nobody should have to fight to be taken seriously about this. The treatments exist. The evidence exists. You just need someone to lay it out plainly.
Learn more about Rose →Systemic HRT (Oestrogen ± Progesterone)
Oestrogen has a well-documented role in maintaining vaginal blood flow, lubrication, and genital sensitivity — all of which directly affect arousal and comfort during sex. Systemic HRT addresses the hormonal withdrawal that drives many of these physical changes, and multiple RCTs show improvements in sexual function as part of broader quality-of-life outcomes. It is not a guaranteed libido fix on its own, but for women whose low desire is tightly coupled with genitourinary symptoms, it is often the logical first step.
Testosterone Therapy
Testosterone is arguably the strongest direct evidence-based treatment for hypoactive sexual desire disorder (HSDD) in postmenopausal women, with a 2019 global consensus statement from the International Society for the Study of Women's Sexual Health explicitly endorsing it for this indication. Meta-analyses of RCTs show statistically significant improvements in satisfying sexual events, desire, and arousal compared to placebo. It is currently used off-label in most countries due to the absence of a licensed female-dose product, but the evidence base is robust and growing.
Local Oestrogen (Vaginal Oestrogen or DHEA)
When low libido is substantially driven by pain during sex — a consequence of genitourinary syndrome of menopause (GSM) — local oestrogen applied directly to vaginal tissue is highly effective at restoring elasticity, moisture, and sensation. Intravaginal DHEA (prasterone), a precursor converted locally to both oestrogen and testosterone, has RCT evidence showing improvements in desire and arousal specifically, not just dryness. Both options deliver minimal systemic absorption, making them suitable for women who cannot or prefer not to use systemic hormones.
Ospemifene (Selective Oestrogen Receptor Modulator)
Ospemifene is an oral SERM licensed specifically for moderate-to-severe dyspareunia due to GSM — and when pain is removed from the equation, desire often follows. RCT data show it improves vaginal tissue health comparably to local oestrogen and reduces the painful intercourse that can condition women's brains to avoid sexual activity altogether. It is a legitimate option for women who are unwilling or unable to use vaginal preparations, and its oral route suits those who find topical application difficult.
Psychosexual Therapy
Sexual desire is not purely hormonal — it is also deeply cognitive and relational, and psychosexual therapy addresses the psychological architecture of desire that no pill touches. Evidence from RCTs and systematic reviews supports its effectiveness for HSDD, particularly when desire loss is entangled with body image shifts, relationship dynamics, or the grief of a changed sense of self that menopause can bring. It works best as part of a combined approach rather than a standalone recommendation, and critically, it should be offered alongside medical treatment — not instead of it.
Pelvic Floor Physical Therapy
A hypertonic or weakened pelvic floor contributes directly to painful sex, reduced arousal, and avoidance patterns that erode desire over time — and pelvic floor physical therapy is the evidence-based treatment for it. Specialised physiotherapists use internal and external techniques to restore muscle function, improve blood flow, and address the protective guarding that many women develop after months of painful intercourse. Observational data and growing RCT evidence support meaningful improvements in sexual pain and function, with effects that compound when combined with hormonal treatment.
Mindfulness-Based Sex Therapy
Mindfulness-based cognitive therapy adapted for sexual dysfunction — sometimes called mindfulness-based sex therapy — has RCT evidence showing it increases genital awareness, reduces spectatoring (the mental self-observation that kills arousal), and improves subjective desire in peri- and postmenopausal women. A landmark series of trials by Lori Brotto and colleagues demonstrated that even brief structured programmes produced durable improvements in sexual response. It is particularly relevant for women whose desire has become disconnected from physical sensation rather than absent altogether.
Addressing Sleep Deprivation and Fatigue
Chronic sleep disruption — one of the most pervasive and underestimated menopause symptoms — suppresses testosterone production, elevates cortisol, and depletes the cognitive and physical energy that desire requires. Studies in both men and women confirm that even modest sleep loss measurably reduces sexual interest within days. Treating sleep as a prerequisite for libido, rather than a separate issue, is not a lifestyle platitude — it is basic endocrinology.
Treatment of Comorbid Depression and Anxiety
Depression and anxiety are among the strongest suppressors of sexual desire known, and both increase in prevalence during perimenopause due to oestrogen's regulatory role in serotonin and GABA systems. The clinical catch is that many antidepressants — particularly SSRIs and SNRIs — are themselves libido suppressors, meaning treatment choice matters enormously. Bupropion is one antidepressant with evidence for a neutral or positive effect on sexual function and is worth discussing with a prescriber in this context.
Flibanserin (for Premenopausal and Some Perimenopausal Women)
Flibanserin is the only FDA-approved oral medication specifically for HSDD, acting on serotonin and dopamine receptors to modulate the neurological balance between sexual excitation and inhibition. Its effect size is modest — clinical trials showed an increase of roughly 0.5 additional satisfying sexual events per month versus placebo — and it is currently approved only for premenopausal women, with limited data in postmenopausal populations. It carries a black box warning for interactions with alcohol and certain medications, so it warrants careful prescriber discussion rather than enthusiasm.
Structured Sensate Focus and Couples-Based Interventions
Sensate focus — a graduated, non-demand touch programme developed originally by Masters and Johnson — remains one of the most evidence-supported behavioural interventions for sexual dysfunction, including desire problems rooted in performance anxiety or disconnection between partners. When one partner is experiencing menopause-related sexual changes, couples-based approaches that reframe the sexual script away from penetration-or-nothing have meaningful evidence behind them. The goal is to rebuild a context in which desire can emerge, rather than demanding it appear on schedule — which, physiologically, it rarely does.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.